Difference between revisions of "Fibrillin-1"
(Created page with "{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" ! {{infobox header}}| '''{{PAGENAME}}''' |- | align="center" ...") |
m |
||
| Line 45: | Line 45: | ||
|- | |- | ||
| Reference | | Reference | ||
| − | | [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids= | + | | [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=20223517&dopt=Abstract PMID:20223517] |
|- | |- | ||
| Notes | | Notes | ||
Revision as of 11:52, 24 June 2014
| Template:Infobox header| Fibrillin-1 | |
|---|---|
| Substrate peptide name | Fibrillin-1 |
| Synonyms | FBN |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Extracellular matrix
Plasma |
| Swissprot ID | P35555 |
| Reactive glutamines | Q3 |
| Reactive lysines | K7 |
| Substrate sequence | EDGFFKI
APQQEA |
| Structure | 1EMN |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:20223517 |
| Notes | |
| Template:Infobox header | | |
